CEACAM1 CEACAM1-L

CI-VAR-00000379Explore in graph →CIViC 3474

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Hepatocellular Carcinoma1
CEACAM1 CEACAM1-L	(prognostic)	Prognostic	B	Supports Poor Outcome	4	submitted	EID9606 In a clinical study including 128 patients, CEACAM1-L dominant expression is significantly associated with decreased recurrence-free survival rate by a multivariate analysis (p = 0.04). Moreover CEACA… (full text at CIViC) PMID 24390710 · Kiriyama et al., 2014 · Open in CIViC	civic
Malignant Colorectal Neoplasm1
CEACAM1 CEACAM1-L	(prognostic)	Prognostic	B	Supports Poor Outcome	4	submitted	EID9605 In a clinical study including 164 patients, CEACAM1-L dominant expression is significantly associated with decreased OS by a multivariate analysis (p = 0.02). PMID 21413011 · Ieda et al., 2011 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.